Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 2/2014

01-08-2014 | Letter to the Editor

Gastric cancer with para-aortic lymph nodes metastasis: curable dissection possible but be cautiously selected

Authors: Tianshu Liu, Yihong Sun, Yan Wang

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2014

Login to get access

Abstract

This is a reply letter to Dr. M Daniele et al. entitled as “gastric cancer with para-aortic lymph nodes metastasis: do not miss a chance of cure!”. Para-aortic lymph node metastasis has been regarded as a pattern of distant metastasis in gastric cancer. Even patients with PAN metastasis undergo extensive lymph nodes, the prognosis is unsatisfactory and the overall survival is not better than the patients receiving palliative chemotherapy. However, for the patients who were responded to the preoperative chemotherapy, subsequent radical gastrectomy performed prolonged survival. Meanwhile, patients who were resistant to the previous chemotherapy were not optimal candidates for curative resection in advanced gastric cancer patients with PAN metastasis. How large with lymph nodes dissection for the patients with initially PAN metastasis after effective neo-chemotherapy is still a controversial issue and needs further large-scale randomized trials.
Literature
1.
go back to reference Yang Q-M, Kawamura T, Itoh H, Bando E, Nemoto M, Akamoto S et al (2008) Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology 55:782–785PubMed Yang Q-M, Kawamura T, Itoh H, Bando E, Nemoto M, Akamoto S et al (2008) Is PET-CT suitable for predicting lymph node status for gastric cancer? Hepatogastroenterology 55:782–785PubMed
2.
go back to reference Lee JH, Paik YH, Lee JS et al (2006) Candidates for curative resection in advanced gastric cancer patients who had equivocal para-aortic lymph node metastasis on computed tomographic scan. Ann Surg Oncol 13(9):1163–1167PubMedCrossRef Lee JH, Paik YH, Lee JS et al (2006) Candidates for curative resection in advanced gastric cancer patients who had equivocal para-aortic lymph node metastasis on computed tomographic scan. Ann Surg Oncol 13(9):1163–1167PubMedCrossRef
3.
go back to reference Tokunaga M, Ohyama S, Hiki N, et al (2010) Can super-extended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 17(8) Tokunaga M, Ohyama S, Hiki N, et al (2010) Can super-extended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol 17(8)
4.
go back to reference Park IH, Kim SY, Kim YW et al (2011) Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol 67(1):127–136PubMedCrossRef Park IH, Kim SY, Kim YW et al (2011) Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement. Cancer Chemother Pharmacol 67(1):127–136PubMedCrossRef
5.
go back to reference Wang Y, Yu YY, Li W et al (2014) A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol 73:1155–1161 Wang Y, Yu YY, Li W et al (2014) A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol 73:1155–1161
Metadata
Title
Gastric cancer with para-aortic lymph nodes metastasis: curable dissection possible but be cautiously selected
Authors
Tianshu Liu
Yihong Sun
Yan Wang
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2512-y

Other articles of this Issue 2/2014

Cancer Chemotherapy and Pharmacology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine